Fund access to GLP-1 medications through the NHS for women with PCOS
Studies highlight the effectiveness of GLP-1 medications for women with PCOS. We think funding access to GLP-1 treatments, without restrictive BMI criteria or tier system barriers, would improve care and outcomes for these patients.
Signatures
840
signatures
Government response threshold (10,000) · 840/10,000
Debate threshold (100,000) · 840/100,000
- 14 JUL 2025Petition closedFinal total: 840 signatures
- 14 JAN 2025Petition opened for signatures
Background
Studies reveal that women with PCOS have higher absenteeism, increased unemployment, and a greater risk of disability retirement by age 52.
Without effective preventive treatments like GLP-1, we think there is a greater burden on the NHS due to downstream complications of untreated PCOS later on. This can include diabetes, cardiovascular disease, infertility, mental health issues, and cancer.
We think early intervention is essential to reduce these long-term healthcare costs on the NHS.